Eli Lilly and Company (FRA:LLY)
Germany
· Delayed Price · Currency is EUR | Market Cap | 655.21B |
| Revenue (ttm) | 43.51B |
| Net Income (ttm) | 10.23B |
| Shares Out | n/a |
| EPS (ttm) | 11.31 |
| PE Ratio | 64.05 |
| Forward PE | n/a |
| Dividend | 5.05 (0.69%) |
| Ex-Dividend Date | Feb 14, 2025 |
| Volume | 46 |
| Average Volume | 489 |
| Open | 727.10 |
| Previous Close | 728.70 |
| Day's Range | 724.40 - 730.30 |
| 52-Week Range | 616.90 - 888.80 |
| Beta | n/a |
| RSI | 51.14 |
| Earnings Date | May 1, 2025 |
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Ja... [Read more]
Financial Performance
In 2024, Eli Lilly and Company's revenue was $45.04 billion, an increase of 32.00% compared to the previous year's $34.12 billion. Earnings were $10.59 billion, an increase of 102.08%.
Financial numbers in USD Financial StatementsNews
Eli Lilly sues telehealth companies selling compounded Zepbound, Mounjaro
Eli Lilly is suing four telemedicine companies selling compounded versions of its blockbuster obesity drug Zepbound and its diabetes treatment Mounjaro, escalating its battle against unauthorized sell...
Tech sector soars: The revival of Silicon Valley giants
Sector Overview Today's market paints a vibrant picture, led by a robust recovery in the technology sector. Heavyweights Microsoft (MSFT) and Apple (AAPL) have posted gains of 3.38% and 3.65%, respect...
Forget Zepbound: Eli Lilly Has Its Next Billion-Dollar Weight Loss Drug
Novo: On Track To The Mid $40s While Loosing Market Share To Eli Lilly
Eli Lilly challenges Novo's dominance in diabetes and obesity drugs.
Stocks making the biggest moves premarket: Boeing, Tesla, BP, Eli Lilly and more
These are the stocks posting the largest moves in premarket trading.
Direxion's Eli Lilly-Focused Bull And Bear Funds Offer Speculative Alternatives
Amid a challenging political and economic environment , pharmaceutical giant Eli Lilly and Company (NYSE: LLY) may offer a potential haven in the storm. Fundamentally, the healthcare sector is genera...
Direxion's Eli Lilly-Focused Bull And Bear Funds Offer Speculative Alternatives
Amid a challenging political and economic environment, pharmaceutical giant Eli Lilly and Company LLY may offer a potential haven in the storm. Fundamentally, the healthcare sector is generally resili...
Is Eli Lilly Stock Going to $900? 1 Wall Street Analyst Thinks So.
Eli Lilly sues four telehealth sites selling compounded Zepbound, Mounjaro
Eli Lilly & Co. is suing four telehealth companies selling compounded versions of Lilly's weight-loss drug Zepbound and its diabetes drug Mounjaro.
Lilly sues four compounders over copies of weight-loss drugs
Eli Lilly said on Wednesday it had sued four compounders for selling unapproved products containing tirzepatide, after a U.S. judge last month blocked pharmacies from making copies of its weight-loss ...
Is Eli Lilly Stock a Buy?
The competitive landscape for GLP-1 agonist weight loss drugs has undergone a significant shake-up.
Eli Lilly Sues 4 GLP-1 Telehealth Startups, Escalating War on Knockoff Drugs
Pharmaceutical giant Eli Lilly alleges the companies are selling off-brand versions of its best-selling diabetes and weight-loss drugs, Mounjaro and Zepbound.
Eli Lilly, Vertex, AbbVie and More Pharma Stocks to Own as Tariffs Loom
Trump's tariff policy is the latest uncertainty to plague the pharmaceutical sector.
Novo Nordisk Just Leapfrogged Eli Lilly With A Weight-Loss Pill; Shares Pop
Novo Nordisk stock popped Tuesday on reports it's asked the FDA to approve its weight-loss pill, an oral version of Wegovy.
Novo Nordisk slides after Eli Lilly's results for oral weight loss drug—orforglipron
Novo Nordisk Shares Fall After Data From New Eli Lilly Pill
Shares fell after Eli Lilly announced results of a new pill that could rival the weight-loss potential of the Danish giant's blockbuster shots.
5 Reasons To Buy Eli Lilly
LLY, NVO and AMGN Forecast – Pharma Stocks to Open Mixed
The three pharma stocks in this analysis all look a bit mixed in the premarket, after seeing some momentum late last week. This is especially true with LLY, as you will see on the charts.
US Stocks Likely To Open Lower: 'Best And Worst Days Tend To Occur Near The Same Time,' Says Expert
U.S. stock futures fell on Monday, following a holiday-shortened week that ended with a mixed performance on Thursday. Major benchmark indices were trading lower in the premarket session. Chinese Mini...
Dow Dips Over 500 Points, Down For 3rd Straight Session As UnitedHealth Tanks: Greed Index Remains In 'Extreme Fear' Zone
The CNN Money Fear and Greed index remained in the “Extreme Fear” zone on Friday. U.S. stocks settled mostly lower on Thursday, with the Dow Jones index falling more than 500 points during the session...
Notable healthcare headlines for the week: UnitedHealth, Eli Lilly, J&J in focus
Stocks dropped this holiday-shortened week under tariff tensions and U.S. economic policies.
Eli Lilly: A New Leader In Weight Loss Drugs Is Clearly Emerging
Prediction: Eli Lilly's Newest GLP-1 Drug Will Be a Game-Changer for the Stock
Benzinga Bulls And Bears: Netflix, UnitedHealth, Eli Lilly — And Market Volatility Continues
Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories. U.S. markets faced heightened volatility this week as the Trump admin...
